Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 12, 2016, Pages 2264-2269

  Yadav, Hemang ^a   Peters, Steve G ^a   Keogh, Karina A ^a   Hogan, William J ^a   Erwin, Patricia J ^a   West, Colin P ^a   Kennedy, Cassie C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic; Bone marrow transplant; Bronchiolitis obliterans; Hematopoietic stem cell transplantation; Obliterative bronchiolitis

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIOLITIS OBLITERANS; COUGHING; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INFECTION; META ANALYSIS; MULTICENTER STUDY (TOPIC); PAIN; PNEUMONIA; PNEUMOTHORAX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TREATMENT OUTCOME;

EID: 85000936581     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.08.027     Document Type: Article

References (33)

1. 1 Ryu, J.H., Myers, J.L., Swensen, S.J., Bronchiolar disorders. Am J Respir Crit Care Med 168 (2003), 1277–1292.
2. 2 Au, B.K., Au, M.A., Chien, J.W., Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17 (2011), 1072–1078.
3. 3 Dudek, A.Z., Mahaseth, H., DeFor, T.E., Weisdorf, D.J., Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 9 (2003), 657–666.
4. 4 Christie, J.D., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report—2012. J Heart Lung Transplant 31 (2012), 1073–1086.
5. 5 Perez, T., Remy-Jardin, M., Cortet, B., Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 157 (1998), 1658–1665.
6. 6 van Rooy, F.G., Rooyackers, J.M., Prokop, M., Houba, R., Smit, L.A., Heederik, D.J., Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. Am J Respir Crit Care Med 176 (2007), 498–504.
7. 7 Ghanei, M., Mokhtari, M., Mohammad, M.M., Aslani, J., Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol 52 (2004), 164–169.
8. 8 King, M.S., Eisenberg, R., Newman, J.H., et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med 365 (2011), 222–230.
9. 9 Parmet, A.J., Von Essen, S., Rapidly progressive, fixed airway obstructive disease in popcorn workers: a new occupational pulmonary illness?. J Occup Environ Med 44 (2002), 216–218.
10. 10 Kreiss, K., Gomaa, A., Kullman, G., Fedan, K., Simoes, E.J., Enright, P.L., Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med 347 (2002), 330–338.
11. 11 Barker, A.F., Bergeron, A., Rom, W.N., Hertz, M.I., Obliterative bronchiolitis. N Engl J Med 370 (2014), 1820–1828.
12. 12 Estenne, M., Maurer, J.R., Boehler, A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002), 297–310.
13. 13 Meyer, K.C., Raghu, G., Verleden, G.M., et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 44 (2014), 1479–1503.
14. 14 Bergeron, A., Belle, A., Chevret, S., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 39 (2007), 547–553.
15. 15 Bergeron, A., Chevret, S., Chagnon, K., et al. Budesonide/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med 191 (2015), 1242–1249.
16. 16 Williams, K.M., Cheng, G.S., Pusic, I., et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant 22 (2016), 710–716.
17. 17 Norman, B.C., Jacobsohn, D.A., Williams, K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 46 (2011), 1369–1373.
18. 18 Brownback, K.R., Simpson, S.Q., Pitts, L.R., et al. Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apher 31 (2016), 347–352.
19. 19 Sengsayadeth, S.M., Srivastava, S., Jagasia, M., Savani, B.N., Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1479–1487.
20. 20 Khalid, M., Al Saghir, A., Saleemi, S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 25 (2005), 490–493.
21. 21 Lam, D.C., Lam, B., Wong, M.K., et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT—a randomized double-blinded placebo-controlled study. Bone Marrow Transplant 46 (2011), 1551–1556.
22. 22 Kingah, P.L., Muma, G., Soubani, A., Azithromycin improves lung function in patients with post-lung transplant bronchiolitis obliterans syndrome: a meta-analysis. Clin Transplant 28 (2014), 906–910.
23. 23 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, T.P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
24. 24 Aguilar, P.R., Michelson, A.P., Isakow, W., Obliterative bronchiolitis. Transplantation 100 (2016), 272–283.
25. 25 Hankinson, J.L., Odencrantz, J.R., Fedan, K.B., Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999), 179–187.
26. 26 Pena, T., Ansari, S., Soubani, A., Effect of azithromycin on the course of Fev1 in bronchiolitis obliterans syndrome after stem cell transplantation?. Am J Respir Crit Care Med, 183, 2011, A4665.
27. 27 Wan, X., Wang, W., Liu, J., Tong, T., Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 14, 2014, 135.
28. 28 Kurdowska, A., Noble, J.M., Griffith, D.E., The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. J Antimicrob Chemother 47 (2001), 867–870.
29. 29 Kanai, K., Asano, K., Hisamitsu, T., Suzaki, H., Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 23 (2004), 671–678.
30. 30 Tateda, K., Comte, R., Pechere, J.C., Kohler, T., Yamaguchi, K., Van Delden, C., Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 (2001), 1930–1933.
31. 31 Yamasawa, H., Oshikawa, K., Ohno, S., Sugiyama, Y., Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 30 (2004), 569–575.
32. 1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res, 12, 2011, 40.
33. 33 Sterne, J.A., Sutton, A.J., Ioannidis, J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 343, 2011, d4002.